CADL — Candel Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $151.73m
- $137.59m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.125 | 0.125 | 0.125 | 0.125 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 9.16 | 13.9 | 25.9 | 34.8 | 38.4 |
Operating Profit | -9.04 | -13.8 | -25.7 | -34.7 | -38.4 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -8.24 | -17.7 | -36.1 | -18.8 | -37.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -8.24 | -17.7 | -36.1 | -18.8 | -37.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -8.24 | -17.7 | -36.1 | -18.8 | -37.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.24 | -17.7 | -36.1 | -18.8 | -37.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.296 | -0.636 | -1.88 | -0.652 | -1.3 |